CNCCurrency
GLP-1 Specialist
The Smartest Exit in the Gray Market
Let’s be direct about what likely happened here, because the industry commentary is dancing around it.
Peptide Sciences built a business that, by all available e-commerce data, generated revenue in the hundreds of millions of dollars over its lifetime. They did this by selling research chemicals in a regulatory gray zone where enforcement was sporadic and penalties were manageable.
Then three things changed simultaneously:
- The highest-margin products (GLP-1s) became legally untouchable. New legislation and 50+ warning letters made continued sales of semaglutide, tirzepatide, and retatrutide an invitation to federal prosecution rather than a calculated risk.
- The enforcement apparatus escalated from letters to raids. Amino Asylum getting their warehouse raided by the FDA in June 2025 sent a message that the era of “we’ll send you a letter and you’ll ignore it” was over.
- The quality facade cracked. Independent testing from the scammers manipulating test results for profit at Finnrisk exposed product quality issues that undermined the brand’s core value proposition: that you were getting pharmaceutical-grade products from a scientifically rigorous supplier.
As we noted in our initial analysis on X: “Peptide Sciences made a quarter billion and walked away at the top. Why fight the FDA in court for a decade when you can just close the laptop and retire? Smartest exit in the gray market.”
This isn’t a tragedy. It’s a business decision.https://thepeptidelist.suspicious-l...ad-inside-the?r=7l77vf&_src_ref=glp1forum.com
Last edited: